Key facts
- It has raised $3.6M; the latest was Early Stage VC ($3.5M) in Dec 2025.
- Notable investors include CureDuchenne Ventures, National Science Foundation Innovation Corps Program, Ohio State Early Investor Network, The Ohio State University.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for DNA Nanobots
- ·The full record, as it builds
Funding rounds
No funding rounds for DNA Nanobots are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DNA Nanobots
Developer of non-viral nanoscale biological delivery systems intended for therapeutic and research purposes. The company's technology uses programmable DNA-based nanostructures, rational molecular design, and sequence-specific assembly to encapsulate and transport genetic material, gene-editing components, and other molecular payloads, with controllable size, targeting ligands, and release mechanisms, enabling clients to study, develop, and evaluate targeted delivery approaches while reducing reliance on viral vectors.
- Sector
- Healthcare
- HQ
- Powell, OH, United States
- Founded
- 2021
- Employees
- 10
- Website
- dnananobots.com/
- Ownership
- Privately Held (backing)
DNA Nanobots doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DNA Nanobots shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DNA Nanobots in its N-PORT filings yet. We sweep new filings monthly.